Titre
Indications for electroconvulsive treatment in schizophrenia: a systematic review.
Type
article
Institution
Externe
Périodique
Auteur(s)
Pompili, M.
Auteure/Auteur
Lester, D.
Auteure/Auteur
Dominici, G.
Auteure/Auteur
Longo, L.
Auteure/Auteur
Marconi, G.
Auteure/Auteur
Forte, A.
Auteure/Auteur
Serafini, G.
Auteure/Auteur
Amore, M.
Auteure/Auteur
Girardi, P.
Auteure/Auteur
Liens vers les personnes
ISSN
1573-2509
Statut éditorial
Publié
Date de publication
2013-05
Volume
146
Numéro
1-3
Première page
1
Dernière page/numéro d’article
9
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
Electroconvulsive therapy (ECT) is a medical treatment that is most effective for mood disorders (Bipolar Disorder and Major Depression). It has also been shown to be an effective treatment for schizophrenia accompanied by catatonia, extreme depression, mania and other affective components. ECT is currently under-used in many psychiatric settings due to its stigmatized perception by patients and mental health professionals. However, many unanswered questions remain regarding its role in the management of patients with schizophrenia.
Evaluate the main indications of ECT in subjects suffering from schizophrenia.
Investigate the efficacy and the main indications of ECT in the treatment of schizophrenic patients, evaluate its effects in the short-term and the long-term, compare ECT treatment with pharmacotherapy, and assess the effects of treatment with ECT.
A systematic review of the literature was conducted on the use of ECT for schizophrenia. Thirty one articles from peer-reviewed journals were identified, and the most relevant articles were selected for this review.
The most common indication for using ECT for schizophrenia patients was to augment pharmacotherapy, while the most common accompanying symptoms were, in order, catatonia, aggression and suicide. Catatonic patients responded significantly better to ECT than patients with any other subtype of schizophrenia. The combination of ECT with pharmacotherapy can be useful for drug-resistant patients. The use of an ECT-risperidone combination or ECT-clozapine combination in patients non-responsive to prior pharmacotherapy was found to be most effective.
This review indicates that ECT, combined with pharmacotherapy, may be a viable option for a selected group of patients with schizophrenia. In particular, the use of ECT is recommended for drug-resistant patients, for schizophrenic patients with catatonia, aggression or suicidal behavior, and when rapid global improvement and reduction of acute symptomatology are required.
Evaluate the main indications of ECT in subjects suffering from schizophrenia.
Investigate the efficacy and the main indications of ECT in the treatment of schizophrenic patients, evaluate its effects in the short-term and the long-term, compare ECT treatment with pharmacotherapy, and assess the effects of treatment with ECT.
A systematic review of the literature was conducted on the use of ECT for schizophrenia. Thirty one articles from peer-reviewed journals were identified, and the most relevant articles were selected for this review.
The most common indication for using ECT for schizophrenia patients was to augment pharmacotherapy, while the most common accompanying symptoms were, in order, catatonia, aggression and suicide. Catatonic patients responded significantly better to ECT than patients with any other subtype of schizophrenia. The combination of ECT with pharmacotherapy can be useful for drug-resistant patients. The use of an ECT-risperidone combination or ECT-clozapine combination in patients non-responsive to prior pharmacotherapy was found to be most effective.
This review indicates that ECT, combined with pharmacotherapy, may be a viable option for a selected group of patients with schizophrenia. In particular, the use of ECT is recommended for drug-resistant patients, for schizophrenic patients with catatonia, aggression or suicidal behavior, and when rapid global improvement and reduction of acute symptomatology are required.
PID Serval
serval:BIB_90A2D327B41F
PMID
Date de création
2023-06-13T14:37:40.839Z
Date de création dans IRIS
2025-05-21T01:13:34Z